Suboptimal dosing of opioid agonist treatments - a literature review

被引:0
|
作者
Al-Dewaissan, Farah B. A. A. [1 ]
Hill, Duncan [1 ,2 ]
Evans, Louise [1 ]
Luz, Tatiana C. B. [1 ]
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[2] NHS Lanarkshire, Bothwell, Scotland
关键词
Methadone; Buprenorphine; Maintenance dosing; Opioid dependence; Literature; OPIATE ADDICTS; COMMUNITY PHARMACIES; COST-EFFECTIVENESS; NATIONAL-SURVEY; DRUG MISUSE; METHADONE; ENGLAND; BUPRENORPHINE; PRACTITIONERS; MANAGEMENT;
D O I
暂无
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Opioid Agonist Treatments (OAT) are used to help with the treatment of patients with issues of dependence to opioid substances. These medications (methadone and buprenorphine) have therapeutic ranges which are commonly referenced and referred to in text and guidelines. Suboptimal dosing (i.e. dosing below the therapeutic level) has been recorded in a few texts. Suboptimal dosing can have an effect on the successive treatment, especially if there are no clear reasons for this (valid reasons can be up titration of dose and detoxification). Methods: This paper looks at the published literature to determine the common prevalence of sub optimal doses of OAT. Results: A limited number of texts were identified that looked at sub optimal dosing in population groups. The results varied between papers but showed a high degree of low dosing. The review also looked at differences between prescribing of methadone and buprenorphine to determine if the medications have a difference between suboptimal rates. Conclusions: Suboptimal dosing for OAT found in the papers is common place in substance misuse services within the UK.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [31] Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995-2009
    Schwartz, Robert P.
    Gryczynski, Jan
    O'Grady, Kevin E.
    Sharfstein, Joshua M.
    Warren, Gregory
    Olsen, Yngvild
    Mitchell, Shannon G.
    Jaffe, Jerome H.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 103 (05) : 917 - 922
  • [32] Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
    Kouyoumdjian, Fiona G.
    Patel, Alexandra
    To, Matthew J.
    Kiefer, Lori
    Regenstreif, Leonora
    PLOS ONE, 2018, 13 (02):
  • [33] Development of Dual MOR Agonist/DOR Antagonists as Novel Treatments for Opioid Use Disorder
    Pasternak, Annie
    Reich, Jeffrey
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [34] Challenges for the implementation of injectable opioid agonist treatment: a scoping review
    Schwarz, Tanja
    Akartuna, Deniz
    Busch, Martin
    Krausz, R. Michael
    Uhl, Alfred
    HARM REDUCTION JOURNAL, 2024, 21 (01)
  • [35] A review of the properties of spiradoline:: A potent and selective κ-opioid receptor agonist
    Wadenberg, MLG
    CNS DRUG REVIEWS, 2003, 9 (02): : 187 - 198
  • [36] Global opioid agonist treatment: a review of clinical practices by country
    Jin, Harry
    Marshall, Brandon D. L.
    Degenhardt, Louisa
    Strang, John
    Hickman, Matt
    Fiellin, David A.
    Ali, Robert
    Bruneau, Julie
    Larney, Sarah
    ADDICTION, 2020, 115 (12) : 2243 - 2254
  • [37] INTRAVENOUS VERSUS SUBCUTANEOUS DOSING OF EPOETIN - A REVIEW OF THE LITERATURE
    ASHAI, NI
    PAGANINI, EP
    WILSON, JM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (02) : 23 - 31
  • [38] Antiarrhythmic Drug Dosing in Children-Review of the Literature
    Oeffl, Nathalie
    Schober, Lukas
    Faudon, Patrick
    Schweintzger, Sabrina
    Manninger, Martin
    Koestenberger, Martin
    Sallmon, Hannes
    Scherr, Daniel
    Kurath-Koller, Stefan
    CHILDREN-BASEL, 2023, 10 (05):
  • [39] Dosing considerations with amifostine: A review of the literature and clinical experience
    Dorr, RT
    Holmes, BC
    SEMINARS IN ONCOLOGY, 1999, 26 (02) : 108 - 119
  • [40] Suboptimal Dosing of Strattera (Atomoxetine) for ADHD Patients
    Clemow, David B.
    POSTGRADUATE MEDICINE, 2014, 126 (05) : 197 - 199